Edward Wos, DO
Hematology & Oncology · Bismarck, NDNPI 1457429680
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,119 of the $1,349 with a category attached, or 83.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $404 and has fallen 55.7% since, to $179 in 2025.
Across 75 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$262
- Pfizer$165
- AstraZeneca$89
- Lilly USA, LLC$80
- Seagen Inc.$71
- AVEO Pharmaceuticals, Inc.$70
- plus $613 from 20 others
What the payments were for
- Food & beverage$1,11983%
- Education$23017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $262 |
| Pfizer | 10 | $165 |
| AstraZeneca(2 entities) | 5 | $89 |
| Lilly USA, LLC | 5 | $80 |
| Seagen Inc. | 4 | $71 |
| AVEO Pharmaceuticals, Inc. | 4 | $70 |
| Bristol Myers Squibb | 4 | $61 |
| Gilead(2 entities) | 3 | $58 |
| Merck | 3 | $55 |
| Incyte Corporation | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Daiichi Sankyo Inc. | 3 | $46 |
| AbbVie | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| EMD Serono, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Clovis Oncology, Inc. | 2 | $29 |
| GSK | 1 | $18 |
| Epizyme, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Immunomedics, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,349 in reported general payments places this provider in the 65th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 53 | $902,300 |
| CalquenceAcalabrutinib Maleate | 40 | $481,344 |
| InlytaAxitinib | 19 | $312,098 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $307,664 |
| JakafiRuxolitinib Phosphate | 12 | $168,737 |
| ErleadaApalutamide | 12 | $164,409 |
| GleevecImatinib Mesylate | 12 | $118,077 |
| EliquisApixaban | 88 | $56,073 |
| Abiraterone Acetate | 30 | $50,763 |
| XareltoRivaroxaban | 27 | $15,766 |
| Imatinib Mesylate | 20 | $5,995 |
| Hydroxyurea | 83 | $2,207 |
| Dexamethasone | 65 | $665 |
| Prednisone | 64 | $489 |
| Prochlorperazine Maleate | 25 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $61 | $902,30053 claims |
| AstraZenecaCalquence | $89 | $481,34440 claims |
| PfizerInlyta, Eliquis | $165 | $368,171107 claims |
| GSKOjjaara | $18 | $307,66412 claims |
| Johnson & JohnsonErleada, Xarelto | $262 | $180,17539 claims |
| Incyte CorporationJakafi | $48 | $168,73712 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $33727 claims |
| Lilly USA, LLCOlanzapine | $80 | $19613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Bismarck
- Peter KurnialiBismarck$8K
- Matthew McGeeBismarck$3K
- Thandiwe GrayBismarck$2K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
- John ReynoldsBismarck$2K
- Alexander JohnsonBismarck$1K
- Aaron LuebkeBismarck$829
- David Oladele-BankoleBismarck$16
- Baruti SerabeBismarck$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.